PROTILLION BIOSCIENCES, INC.

Redwood City, CA · Biotech · Private

Prot-MaP, a high-throughput platform for quantitative protein binding measurement across large antibody/protein libraries using in-situ transcription and translation on DNA sequencing flow cells

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Headquarters
Redwood City, CA
Total capital
$2.8M
Federal grants
$2.8M
3 awards · 2020–2022
Rank in peer group#25 of 36
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
8 pending

Capital timeline

202020212022FEDERAL ↑EQUITY ↓Cumulative $2.8M$248K$1.7M$855K
202020212022FEDERAL ↑EQUITY ↓Cumulative $2.8M$248K$1.7M$855K

Latest events

  • Federal grantHealth and Human S · Phase II · Quantitative high-throughput methods for antibody fragment optimization and discovery$855K
  • Federal grantHealth and Human S · Phase II · Quantitative high-throughput methods for antibody fragment optimization and discovery$1.7M
  • Federal grantHealth and Human S · Phase I · Large-Scale, Quantitative Protein Affinity Assays on a High-Throughput DNA Sequencing Chip$248K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 36 peers

Line = median

Biotech · Platform

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 8
  • PendingMethods, Systems, And Compositions Of Generating And Analyzing Polypeptide LibrariesUSPTOApplication 19552778
  • PendingMethods, Systems, And Compositions Of Generating And Analyzing Polypeptide LibrariesUSPTOApplication 19552708
  • PendingMethods, Systems, And Compositions Of Generating And Analyzing Polypeptide LibrariesUSPTOApplication 18570580
Show all 8 patent records
  • Methods, Systems, And Compositions Of Generating And Analyzing Polypeptide LibrariesJul 2, 2026 · Application 19552778Pending
  • Methods, Systems, And Compositions Of Generating And Analyzing Polypeptide LibrariesJul 2, 2026 · Application 19552708Pending
  • Methods, Systems, And Compositions Of Generating And Analyzing Polypeptide LibrariesAug 22, 2024 · Application 18570580Pending
  • Systems And Methods For Assaying A Plurality Of PolypeptidesSep 14, 2023 · Application 18007032Pending
  • Methods, Systems, And Compositions Of Generating And Analyzing Polypeptide LibrariesApplication PCTUS2022033437Pending
  • Systems And Methods For Assaying A Plurality Of PolypeptidesApplication PCTUS2021043297Pending
  • Methods, Systems, And Compostions Of Generating And Analyzing Polypeptide LibrariesApplication 63210905Pending
  • Methods For Assaying A Plurality Of PolypeptidesApplication 63057754Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .